PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
16.52%
Positive EBIT growth while AVXL is negative. John Neff might see a substantial edge in operational management.
16.52%
Positive operating income growth while AVXL is negative. John Neff might view this as a competitive edge in operations.
16.61%
Positive net income growth while AVXL is negative. John Neff might see a big relative performance advantage.
17.14%
Positive EPS growth while AVXL is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
17.14%
Positive diluted EPS growth while AVXL is negative. John Neff might view this as a strong relative advantage in controlling dilution.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Dividend reduction while AVXL stands at 0.00%. Joel Greenblatt would question the firm’s cash flow stability or capital allocation decisions.
9.84%
Positive OCF growth while AVXL is negative. John Neff would see this as a clear operational advantage vs. the competitor.
13.18%
Positive FCF growth while AVXL is negative. John Neff would see a strong competitive edge in net cash generation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-2671.03%
Negative 10Y OCF/share CAGR while AVXL stands at 31.48%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
90.48%
Positive OCF/share growth while AVXL is negative. John Neff might see a comparative advantage in operational cash viability.
83.42%
Positive 3Y OCF/share CAGR while AVXL is negative. John Neff might see a big short-term edge in operational efficiency.
-2587.91%
Negative 10Y net income/share CAGR while AVXL is at 60.72%. Joel Greenblatt sees a major red flag in long-term profit erosion.
90.30%
Positive 5Y CAGR while AVXL is negative. John Neff might view this as a strong mid-term relative advantage.
86.48%
Positive short-term CAGR while AVXL is negative. John Neff would see a clear advantage in near-term profit trajectory.
1551.35%
Below 50% of AVXL's 4765.19%. Michael Burry would suspect poor capital allocation or persistent net losses eroding long-term equity build-up.
-71.69%
Negative 5Y equity/share growth while AVXL is at 112.89%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
-47.82%
Negative 3Y equity/share growth while AVXL is at 23.71%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
13.10%
Asset growth well under 50% of AVXL's 57.30%. Michael Burry sees the competitor as far more aggressive in building resources or capacity.
15.36%
Under 50% of AVXL's 69.99%. Michael Burry raises concerns about the firm’s ability to build intrinsic value relative to its rival.
-14.09%
We’re deleveraging while AVXL stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-7.82%
Our R&D shrinks while AVXL invests at 29.82%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-4.34%
We cut SG&A while AVXL invests at 4.83%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.